2024-510707-11-00
Registration, authorisation of a trial application, trial start, result disclosure and marketing authorisation are different facts. The dossier claims neither clinical efficacy nor safety, deployment or causality.
CTIS record ≠ efficacy ≠ marketing authorisationTerms count only in allowlisted public CTIS fields. Sponsor, medical condition, phase or a generic software reference alone is not AI evidence.
“Artificial Intelligence driven personalisation of radiotherapy and concomitant androgen deprivation therapy for prostate cancer patients”
“The individualization of radiotherapy (RT) based on prostate-specific membrane antigen positron emission tomography / computed tomography (PSMA PET/CT) imaging and a multimodal artificial intelligence (MMAI) system in terms de-intensification of hormonal therapy in parallel to ultra-hypofractionated RT and dose escalation to the prostate has no decreased disease-free survival.…”
A status in one country is not transferred to another. Decision dates and status histories remain separate source facts.
Decisions29 May 2024 · Authorized
Country statusCyprus · Authorised
Decisions26 February 2025 · Authorized
Country statusCyprus · Authorised
The chronicle sorts published CTIS events. i6eal observation times follow on a separate clock.
No result disclosure is published in this projection. This means neither that results do not exist nor that a deadline has been missed.
The public CTIS record remains authoritative. The i6eal files are a deterministic, bounded projection.
i6eal (2026): EU AI Studies Monitor, CTIS trial 2024-510707-11-00, data state 23 July 2026. https://i6eal.de/en/tools/ki-studienmonitor/studie/2024-510707-11-00/These tools complement the current result.